Tang, Zhenghai
Veillette, André http://orcid.org/0000-0003-1159-4345
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research
Article History
First Online: 10 November 2022
Competing interests
: A.V. received a contract from Bristol Myers Squibb to study the mechanism of action of anti-SLAMF7 antibody elotuzumab in multiple myeloma. He also consulted for Boehringer Ingelheim on SIRPα-CD47 blockade. The other author declares no competing interests.